An observational study in Non-Small Cell Lung Cancer, Stage III Lung Cancer and Mediastinal Lymph Node Metastasis, sponsored by Sun Yat-sen University. Completed at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Sun Yat-sen University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Carcinoma, Non-Small-Cell Lung by Sun Yat-sen University — 33 open to participants now, 41 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Sun Yat-sen University.
Among the 103 studies in Carcinoma, Non-Small-Cell Lung by Sun Yat-sen University, this one is the 6th largest by enrollment of the 16 observational ones that give a count, is one of 11 that started in 2019, is one of 16 observational ones, and was the 102nd registered.
7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →33 of the 103 studies in Carcinoma, Non-Small-Cell Lung by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 67 · Phase 3 12 · Phase 4 2
First in 2008; this study’s year is marked. 11 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 336 is above the median of 160 across 1,150 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 80 across the 87 interventional studies, 155 across the 16 observational. Of the 28 that completed or were terminated, 2 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sun Yat-sen University is the lead sponsor of 1,694 studies on the registry; 621 are open to participants now.
6 of the studies in Carcinoma, Non-Small-Cell Lung by Sun Yat-sen University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06426511Sun Yat-sen UniversityctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC | 2026-12-01 |
| NCT06542159Sun Yat-sen UniversityElimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases | 2027-04-21 |
| NCT07630077Sun Yat-sen UniversityTrastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities | 2027-07-01 |
| NCT07204548Sun Yat-sen UniversityThe IVO-LUNG Study | 2027-10 |
| NCT06563999Sun Yat-sen UniversityNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. | 2027-11-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 103 studies in Carcinoma, Non-Small-Cell Lung by Sun Yat-sen University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This retrospective observational study examines whether the number and location of involved lymph node stations before treatment help predict pathological response and survival in patients with resectable stage III N2 non-small cell lung cancer. The study includes 336 patients treated with neoadjuvant chemotherapy combined with a PD-1 or PD-L1 inhibitor at seven hospitals in China between January 2019 and January 2024. Patients who did not undergo planned surgery because of disease progression or serious adverse events remain in the cohort.
The nodal features are the number of distinct involved N1 and N2 stations, the individual stations involved, and the lung lobe or lobes containing the primary tumor. Each station is counted once. Statistical models will estimate lobe-specific higher-risk and lower-risk station patterns and the corresponding numbers of involved stations. These patterns are derived from the clinical data and are not assigned in advance according to presumed lymphatic drainage.
Primary outcomes are pathological complete response, major pathological response, event-free survival, and overall survival. The principal station-risk map is based on predicted 48-month event-free risk, with 36-month estimates as a supplementary analysis. Models based on clinical features, clinical features plus station counts, and additional lobe-specific station patterns will be compared using internal validation.
This is a separate secondary analysis that partly reuses participants from an earlier registered study and includes updated and additional data. Outcomes from the source cohort have already been examined. The registration documents the revised retrospective analysis and does not establish that its methods were specified before those outcomes were known. Treatment was selected by the treating clinicians, and this study assigns no treatment.
STUDY POPULATION AND DATA This multicenter retrospective cohort includes 336 adults with pathologically confirmed NSCLC and clinically resectable cT1-4N2M0 disease under the AJCC eighth edition who received neoadjuvant PD-1 or PD-L1 inhibitor-based chemotherapy from January 2019 to January 2024 at seven Chinese hospitals. The full treated cohort is used for survival and treatment-completion outcomes. Pathological outcomes use the relevant evaluable resection specimens; 326 patients underwent surgery in the source cohort. Sample size is determined by available eligible records. Outcome data collection was completed on September 1, 2026, and data verification was completed on October 1, 2026. Individual survival follow-up ends at the documented event or censoring assessment in the completed dataset. No study-specific treatment or biospecimen collection is assigned.
This separately registered secondary analysis partly overlaps with NCT06292052 and includes updated and additional records. Previously examined findings and revised analyses will be identified in reporting. The overlapping earlier cohort is not an independent validation cohort. Ethics approval G2024-017-01 from the Institutional Review Board of Sun Yat-sen University Cancer Center covers the seven-center data collection and this revised analysis, with waiver of individual informed consent.
PRETREATMENT STATION FEATURES Pretreatment nodal involvement is abstracted from CT and/or FDG PET/CT interpreted by at least two radiologists, supplemented by EBUS-guided biopsy or mediastinoscopy when performed. Evidence includes positive nodal pathology, CT short-axis diameter of at least 10 mm, PET uptake judged suspicious in the documented staging assessment, or other radiographic features suspicious for malignant involvement. Imaging-suspected and biopsy-confirmed disease are recorded separately. Any documented PET criterion is retained from the source assessment; no unreported numerical SUV threshold is introduced.
The nodal analysis uses the total number of distinct involved N1 and N2 stations, individual station indicators, primary tumor lobe, and lobe-by-station features. Each anatomical station is counted once regardless of how many nodes are present in that station. For tumors involving two lobes, features from both lobes are retained and the corresponding station patterns are combined as a union, with shared stations counted once. Individual station documentation is checked before constructing the total count. Pooled station fields, including a combined stations 11-14 field, are retained as group-level information if they cannot be resolved from source records and are not expanded into individually observed stations. Unassessed stations and unresolved codes are not automatically classified as uninvolved.
PREDICTION MODELS AND RISK PATTERNS Clinical models are compared with models adding station burden and models further adding station identity and lobe-by-station features. Clinical predictors are restricted to information available before the first neoadjuvant dose, including age, sex, smoking history, histology, tumor diameter, clinical T category, tumor lobe, imaging modality, and pretreatment PD-L1 expression where available. Actual treatment cycles, postoperative findings, and adjuvant treatment are not pretreatment predictors.
Penalized logistic regression is used for binary pathological and treatment-completion outcomes, and penalized Cox regression for EFS and OS. The principal lobe-specific station-risk map is derived from adjusted predicted 48-month EFS event risk. Within each training sample, station contributions are evaluated conditional on clinical characteristics and station burden, within observed combinations. Stable contributions above or below the lobe-specific reference are described as relatively higher-risk or lower-risk station patterns. Sparse or unstable patterns remain indeterminate. Numbers of involved stations in each model-derived risk category are evaluated alongside total station burden and continuous predicted risk. Station categories and risk thresholds are learned from training data and applied unchanged to held-out data. Associations are not interpreted as causal effects of individual stations.
Repeated nested five-fold cross-validation is used for internal model evaluation, with penalty tuning in the inner folds. Imputation, encoding, scaling, feature construction, and risk-pattern derivation are restricted to the training portion. Leave-one-center-out analyses assess performance across contributing centers where estimable. No independent external validation cohort is available. Binary models are evaluated by discrimination, calibration, and Brier score. Survival models are evaluated by concordance, 48-month calibration, and censoring-adjusted Brier score. Thirty-six-month estimates are supplementary. All observed follow-up is retained for time-to-event analyses; predictions are not extrapolated beyond supported follow-up, and uncertainty for sparse lobe-station combinations is reported.
ASSOCIATION AND SENSITIVITY ANALYSES Descriptive analyses summarize baseline characteristics and station patterns. Logistic and Cox regression provide adjusted associations with 95% confidence intervals, accounting for contributing center where appropriate. Survival is described with Kaplan-Meier estimates; proportional hazards assumptions are assessed. Supplementary inverse-probability-weighted comparisons of defined nodal-pattern groups use pretreatment covariates, stabilized weights trimmed at the 1st and 99th percentiles, balance checks, and alternative trimming as sensitivity analyses. Outcome-derived groups are evaluated using held-out predictions. Missing baseline covariates are handled by multiple imputation for association analyses and training-only imputation for prediction, with complete-case sensitivity analyses. Sensitivity analyses examine biopsy-confirmed disease, available station coverage, multilobar tumors, and Rx classifications. Across the four primary outcome families, a Bonferroni reference threshold of 0.0125 is used for hypothesis tests; secondary analyses and model-derived classifications remain exploratory.
ENDPOINT ADJUDICATION AND INTERPRETATION Endpoint flags, source dates, and station codes are reconciled against original clinical records using a documented data dictionary before the revised analyses. Discrepancies are not resolved by selecting the coding that best supports an observed result. EFS includes progression preventing surgery, a serious adverse event preventing surgery, postoperative recurrence or progression, and death from any cause. Non-R0 resection alone is not an EFS event. For treatment-completion endpoints, R1, R2, and Rx are classified as non-R0; Rx denotes inability to establish R0 rather than proven residual tumor and is also evaluated separately.
The models estimate response and prognosis among patients treated with neoadjuvant chemoimmunotherapy. Without a treatment comparator, they do not estimate differential benefit from immunotherapy or establish a biological lymphatic mechanism. Model-derived station patterns require independent validation before clinical treatment selection.
Adults with pathologically confirmed NSCLC and clinically resectable cT1-4N2M0 disease (AJCC eighth edition) who received neoadjuvant PD-1 or PD-L1 inhibitor-based chemotherapy between January 2019 and January 2024 at seven participating hospitals in China. Existing records provide a non-probability sample. The full treated cohort includes patients who did not undergo planned surgery because of serious adverse events or progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
336 adults with pathologically confirmed, clinically resectable cT1-4N2M0 NSCLC (AJCC eighth edition) treated with neoadjuvant PD-1 or PD-L1 inhibitor-based chemotherapy at seven Chinese hospitals between January 2019 and January 2024. Patients who did not undergo planned surgery because of serious adverse events or progression remain included. Pretreatment N1 and N2 station burden and lobe-specific station patterns are observed model features. Pathological outcomes are assessed in participants with corresponding evaluable surgical specimens.
Drug: Neoadjuvant chemoimmunotherapy
PD-1 or PD-L1 inhibitor-based chemotherapy administered before planned surgery as part of routine clinical care. Regimens were selected by treating clinicians before this retrospective analysis; the registration assigns no drug regimen.
Pathological complete response (pCR)
Percentage of patients with evaluable surgical specimens who have no viable invasive tumor cells in both the resected primary tumor and all dissected lymph nodes.
Time frame: Up to approximately 8 weeks following completion of neoadjuvant treatment
Major pathological response (MPR)
Percentage of patients with evaluable resected primary tumor specimens who have no more than 10% residual viable tumor in the primary tumor bed. Nodal response is evaluated separately.
Time frame: Up to approximately 8 weeks following completion of neoadjuvant treatment
Event-free survival (EFS)
Time from the first neoadjuvant dose to the earliest of: progression preventing planned surgery (progression confirmation date), a serious adverse event preventing planned surgery (SAE occurrence date), postoperative recurrence or progression (first documented confirmation date), or death from any cause (death date). Non-R0 resection alone is not an event.
Time frame: Up to approximately 10 years
Overall survival (OS)
Time from the first neoadjuvant dose to death from any cause in the full treated cohort. Patients without a recorded death are censored at their last documented date known alive in the completed dataset.
Time frame: Up to approximately 10 years
Lymph node complete pathological response (LN-CR)
Percentage of patients with evaluable dissected lymph node specimens who have no viable tumor cells in all resected lymph nodes.
Time frame: Up to approximately 8 weeks following completion of neoadjuvant treatment
Failure to undergo planned surgery due to serious adverse events or progression
Percentage of the full treated cohort who do not undergo planned resection because of a serious adverse event or disease progression during neoadjuvant treatment.
Time frame: From the first neoadjuvant dose through 6 months after the last neoadjuvant dose
Surgical resection outcome
Percentage of the full treated cohort who either do not undergo planned surgery because of a serious adverse event or disease progression, or undergo resection classified as R1, R2, or Rx. Rx is included operationally because R0 cannot be established; it does not indicate proven residual tumor.
Time frame: From the first neoadjuvant dose through 6 months after the last neoadjuvant dose
Plan to share: Undecided
Ran from Jan 2019 to primary completion in Sep 2026, 92 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →